Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).

Trial Details

NCT ID
NCT04134559
Phase
PHASE2
Sponsor
Allison O'Neill, MD
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Pembrolizumab
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Cincinnati, Ohio, United States|39.12711,-84.51439
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Age: Patients must be \<30 years of age at the time of study enrollment.
  • Diagnosis: Patients must have relapsed/refractory, histologically confirmed HCC to be eligible for enrollment. Patients with hepatocellular neoplas…
  • Disease Status: Participants must have measurable disease by RECIST criteria, defined as at least one lesion that can be accurately measured in at …
  • Performance Level: Karnofsky performance status ≥ 60% for patients ≥ 16 years of age or Lansky ≥ 60% for patients \< 16 years of age.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →